Last updated on March 2019

A 12-week randomized, double-blind, parallel-group, placebo-controlled study to determine the efficacy and safety of biphasic remogliflozin etabonate when administered to subjects with type 2 diabetes mellitus.


Brief description of study

A 12-week randomized, double-blind, parallel-group, placebo-controlled study to determine the efficacy and safety of biphasic remogliflozin etabonate when administered to subjects with type 2 diabetes mellitus.

Detailed Study Description

Using a new oral medication in the same class as Invokana and Farxiga (SGLT2 inhibitors) to demonstrate similar or better efficacy with a better safety profile.

Clinical Study Identifier: TX143207

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.